CRISPR binge-watchers have eyes wide shut. Medicine historian Nathaniel Comfort demolishes for Nature the long-awaited book by the queen of genome editing Jennifer Doudna “A crack in creation”. CRISPR stocks fall after the publication of a small preliminary study on off-target mutations. New Scientist announces as many as 20 human trials will be under way soon, mostly in China.